Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
View Patent ↗The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
1. A method of assigning a risk of worsening renal function to a patient suffering from heart failure, comprising:
performing an assay method that detects NGAL (neutrophil gelatinase-associated lipocalin) on a body fluid sample obtained from said patient, thereby providing an NGAL assay result;
comparing said NGAL assay result to a baseline NGAL result; and
relating the NGAL assay result to the patient's risk of worsening renal function by assigning an increased risk of worsening renal function to said patient when said NGAL assay result is greater than said baseline NGAL result, relative to a risk assigned when said NGAL assay result is less than said baseline NGAL result, or by assigning a decreased risk of worsening renal function to said patient when said NGAL assay result is less than said baseline NGAL result, relative to a risk assigned when said NGAL assay result is greater than said baseline NGAL result.
2. A method according to claim 1 , wherein said baseline NGAL result is determined by performing an assay method that detects NGAL on a body fluid sample obtained from said patient at a time earlier than the time at which the body fluid sample used to provide said NGAL assay result was obtained.
3. A method according to claim 1 , wherein said baseline NGAL result is determined from a population of subjects suffering from heart failure, and said baseline NGAL result is selected to separate said population into a first subpopulation having an increased risk of worsening renal function relative to a second subpopulation.
4. A method according to claim 3 , wherein said baseline NGAL result separates said first subpopulation from said second subpopulation with an odds ratio of at least 2 or more or 0.5 or less.
5. A method according to claim 3 , wherein said baseline NGAL result separates said first subpopulation from said second subpopulation with an odds ratio of at least 3 or more or 0.33 or less.
6. A method according to claim 1 , wherein the assay method comprises performing an immunoassay that detects NGAL.
7. A method according to claim 1 , wherein the body fluid sample is selected from the group consisting of urine, blood, serum, and plasma.
8. A method according to claim 6 , wherein said immunoassay comprises contacting said body fluid sample with a solid phase comprising antibody that detects NGAL, and detecting binding to said antibody.
9. A method according to claim 1 , wherein the method further comprises determining one or more additional variables selected from the group consisting of a serum creatinine level for said patient, a creatinine clearance rate for said patient, a cystatin C level for said patient, and a glomerular filtration rate for said patient; and
wherein the patient's risk of worsening renal function is assigned based on comparing said NGAL assay result to said baseline NGAL result, and on said one or more additional variables.
10. A method according to claim 1 , wherein the method further comprises determining one or more additional variables selected from the group consisting of a urine output level for said patient, age of said patient, the presence or absence of diabetes in said patient, and the presence or absence of hypertension in said patient; and
wherein the patient's risk of worsening renal function is assigned based on comparing said NGAL assay result to said baseline NGAL result, and on said one or more additional variables.